US Patent 9,434,754 (4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile dihydrogen phosphate): Scope, Claim Coverage, and U.S. Patent Landscape
Executive summary: U.S. Patent 9,434,754 is claim-anchored on a single chemical entity: a specific chiral “4-[(5R)-…]-3-fluorobenzonitrile” framework presented as the “dihydrogen phosphate” salt (and equivalents under “pharmaceutically acceptable salt” language). The operative infringement footprint is tightly aligned to this exact salt form (and salts interchangeable under the same claim phrase). The patent landscape around it typically fragments into (i) the same drug substance in alternate salt forms, (ii) polymorph/crystal forms and hydrates, (iii) intermediate chemistry and stereochemistry-enabling steps, and (iv) formulation/device and method-of-use IP. Without the rest of the patent record (specifically the dependent claims, specification definitions, and prosecution history) a complete, definitive mapping of all enforceable claim scope and design-around space cannot be produced.
What exactly does US Patent 9,434,754 claim for the dihydrogen phosphate salt?
Answer: Claim 1 covers the compound:
- 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile dihydrogen phosphate
- plus “a pharmaceutically acceptable salt thereof.”
Core claim elements (coverage map):
- Molecular scaffold: “4-[(5R)-…]-3-fluorobenzonitrile”
- Stereochemistry: explicitly (5R) at the pyrrolo[1,2-c]imidazole substituent position
- Heterocycle/bridge: “6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl”
- Anion form: dihydrogen phosphate
- Salt doctrine overlay: “pharmaceutically acceptable salt thereof” (claim extension that can include other anions, depending on how the specification defines the “thereof”)
Implication for scope: The claim is a Markush-free, structurally specified chemical claim. It is not written as a broad class of salts defined by generic anions, unless “pharmaceutically acceptable salt thereof” in the patent’s claim construction is read broadly to encompass alternate counterions for the same cation. Practically, this often yields enforcement leverage against the named phosphate salt and can also capture other pharmaceutically acceptable salts of the same cation, subject to claim construction and specification support.
Does the “pharmaceutically acceptable salt thereof” broaden infringement beyond dihydrogen phosphate?
Answer: Potentially, but the actual breadth depends on what the “thereof” refers to in the patent record.
Two common constructions:
- Narrow construction: “salt thereof” means salts of the named dihydrogen phosphate compound. That typically yields little additional scope because dihydrogen phosphate is already a salt.
- Broader construction: “salt thereof” means salts of the underlying free base (or parent compound) corresponding to the same cationic entity. That can expand coverage to other anions (e.g., sulfate, citrate, maleate), if supported by the specification and treated as “pharmaceutically acceptable.”
Infringement pressure points:
- If competitors market the same (5R) cation in a non-phosphate salt, coverage can hinge on whether the claim construction treats that as within “pharmaceutically acceptable salt.”
- If competitors market different stereochemistry (e.g., 5S or racemate), the explicit “(5R)” requirement can be a hard design-around if it holds at claim construction.
What structure features create the strongest claim anchor and the most obvious design-around vectors?
Answer: The strongest anchors are the explicit (5R) stereochemistry and the fully specified ring-substitution pattern.
Most direct design-around vectors:
- Stereochemistry change (5R → 5S or racemate): The claim requires (5R). A racemate product still contains (5R) molecules, but infringement for a stereospecific chemical claim often turns on whether the claim reads on the mixture and how the product is defined in the claim scope (this is a claim-construction and factual inquiry).
- Salt change (dihydrogen phosphate → other anion): Coverage depends on the meaning of “pharmaceutically acceptable salt thereof.”
- Cation scaffold deviation: Any change breaking the defined “pyrrolo[1,2-c]imidazole” substitution pattern or the “3-fluorobenzonitrile” core avoids literal coverage. Small substitutions can still risk doctrine-of-equivalents arguments, but literal avoidance is most robust for chemical claims.
What dependent claims and specification details matter for real-world enforceability?
Answer: Not provided in the prompt. Enforceable scope often turns on:
- Dependent claims that specify:
- specific crystal forms/polymorphs of the phosphate salt
- particle size ranges
- hydration state (hydrates/solvates)
- manufacturing steps that yield that salt
- formulation embodiments (tablets, capsules, oral solution)
- Specification definitions of:
- what the “compound” includes (free base vs. salt)
- what anions are “pharmaceutically acceptable”
- how stereochemistry is produced and validated
- Prosecution history:
- narrowing amendments tied to “(5R)” or the phosphate counterion
- statements limiting “salt thereof” breadth
Without the dependent-claim set, claim charting against competitor products can be incomplete and can’t be performed without risk of error.
How does US 9,434,754 typically position against related patent estate components?
Answer: Chemical drug patents with this claim pattern usually sit in a layered estate. The common U.S. IP stack adjacent to a single defined salt form is:
- Substance (drug substance) patents
- same cation with named salts (phosphate and alternates)
- stereochemical claims (enantiomerically enriched)
- Solid-state form patents
- polymorphs, crystal lattices
- hydrates and solvates
- engineered particle properties
- Process patents
- making the (5R) enantiomer
- forming the dihydrogen phosphate salt
- purification steps and isolation of crystal form
- Formulation patents
- dosage forms
- excipient systems
- dissolution-rate improvements
- Use patents
- indications, dosing regimens, combination therapy
This structure impacts clearance and licensing strategy because even if a salt form claim is narrowly interpreted, later-emerging patents can still block commercialization.
What does the claim say about method-of-use or combination therapy?
Answer: Claim 1 as provided is compound-of-the-substance only. It does not recite:
- a therapeutic method
- a patient population
- dosing parameters
- combination partners
Method-of-use and combination claims, if present, would be in dependent claims or separate patents, and must be checked in the full patent record and related family documents.
How strong is the patent for litigation compared with broader class claims?
Answer: Structurally specified chemical claims are often strong on literal infringement because the comparison is deterministic:
- exact scaffold
- exact stereochemistry
- exact salt or included “pharmaceutically acceptable salt” scope
Strength risks usually come from:
- claim construction of “salt thereof”
- validity challenges:
- lack of novelty over prior art salts or stereoisomers
- obviousness of the phosphate salt or enantiomer
- enforceability issues tied to prosecution statements
A structurally narrow claim can still be valuable if the marketed product is the exact salt and the jurisdiction construes “pharmaceutically acceptable salt” broadly. If competitors use a different salt and the construction is narrow, the infringement case can weaken.
What claims could a competitor file to avoid US 9,434,754 while staying close?
Answer: Common clearance approaches for phosphate-salt chemical claims:
- Switch anion to a different pharmaceutically acceptable salt and rely on narrow construction of “salt thereof.”
- Use alternate stereochemical purity strategy if the claim is read stereospecifically and if formulation allows avoiding the (5R) cation as the primary species.
- Target different solid state while still using the same salt: this typically avoids only if the blocking patent is form-specific rather than the core compound salt. Here, the provided claim is for the compound itself, so solid-state modifications alone usually do not avoid literal coverage.
How does this claim likely map to FDA commercialization risk via the Orange Book?
Answer: If the marketed product contains this exact dihydrogen phosphate substance (or a permitted “pharmaceutically acceptable salt” of the same cation), US 9,434,754 is likely to appear in the Orange Book as a listed drug-substance or drug-product patent depending on the filing. For Paragraph IV strategy, the key risk is whether the applicant seeks approval referencing a listed proprietary drug where this patent is still in force for the relevant section of the code.
However, the prompt provides only the claim text, not:
- Orange Book listing status
- expiration date
- patent term adjustments
- pediatric exclusivity
- whether the listed patent is the one relevant to the approved NDA/BLA
Those details cannot be stated reliably without the full patent metadata.
Patent estate analysis: what to look for next to US 9,434,754 in the U.S.?
Answer: The most probative next checks in the U.S. are:
- Same-family patents with:
- different salt counterions
- alternative enantiomer claims
- polymorph/crystal claims
- process claims for forming the dihydrogen phosphate salt
- Continuations/divisionals that broaden or tighten the claim scope
- Related third-party patents that create independent infringement theories:
- if a competitor has a different solid form, they may still infringe process or stereochemistry claims
A full “landscape” needs:
- all claims from US 9,434,754
- inventor/assignee
- application number and filing dates
- family members and their U.S. counterparts
- Orange Book ties and any litigation docket
None of that is available in the prompt.
Key takeaways
- Claim 1 is a single-entity chemical claim covering the named (5R) cation with dihydrogen phosphate and extending to “pharmaceutically acceptable salt thereof,” with breadth that depends on claim construction and specification support.
- The principal design-around axes are (i) anion change (phosphate → other salt) and (ii) stereochemistry change (5R → other stereochemical composition), plus scaffold deviation.
- A complete U.S. landscape and litigation-strength view requires the full patent record (dependent claims, specification definitions, prosecution history) and Orange Book/family mapping, which are not included here.
FAQs
- Does US 9,434,754 cover the free base form or only the dihydrogen phosphate salt?
- If a generic uses a different salt form of the same (5R) cation, does it avoid infringement?
- Are polymorph or hydrate patents likely to be separate from a compound-of-form claim like this?
- How do stereochemistry limitations like “(5R)” affect infringement for racemic drug substance products?
- What U.S. patent family members typically coexist with enantiomeric phosphate salt claims in drug substance estates?
References (APA)
- U.S. Patent 9,434,754.
